Praxis Precision Q3 net loss widens to $94 mln on G&A costs
PRAX•Praxis Precision reported a Q3 net loss of $94.23 million, or $3.23 per share. Cash and investments rose to $1.3 billion, which the company expects to fund operations into 2028.
1. Q3 results and outlook
Operating expenses were $106.91 million. Research and development expenses fell slightly, while general and administrative costs rose sharply, driven by higher personnel, professional and other expenses. Cash and investments increased due to proceeds from a public offering and interest income. FDA reviews of relutrigine and ulixacaltamide are ongoing, with target action dates of December 27, 2026, and January 29, 2027, respectively; topline results from the EMERALD study of relutrigine are expected in Q4 2026.
